News
Eli Lilly, Zepbound
Digest more
Hosted on MSN3d
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders WaryEli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase ...
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...
People taking Zepbound, Eli Lilly’s obesity drug, lost almost 50% more weight than individuals using Novo Nordisk’s ...
Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback